Similar Items: An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non‐Small‐Cell Lung Cancer Harboring Common EGFR Mutations Treated With Afatinib
- MET Dependence Oversteps EGFR Dependence via Balancing Dimerization of the Receptor Tyrosine Kinases in Osimertinib‐Resistant MET‐Amplified, EGFR‐Mutated Non‐Small Cell Lung Cancer
- Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR‐Mutated Advanced NSCLC: The Impact of Post‐Progression Management
- Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China
- Acquired BRAF-AGK Fusion Following Osimertinib Plus Savolitinib in EGFR-Mutated MET-Amplified Non-Small-Cell Lung Cancer: Durable Response to Gefitinib and Trametinib in a Case Report
- Prospective Multicenter Observational Study of Anlotinib in Advanced Non‐Small Cell Lung Cancer: Real‐World Evidence From China
- Poor Outcome of Pediatric Patients with Acute Lymphoblastic Leukemia Harboring Low P16 Deletion Ratio: A Post-Hoc Analysis from a Prospective Cohort